Virus News and Research

Latest Virus News and Research

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

Scientists determine atomic structure of Lassa fever viral protein

Scientists at The Scripps Research Institute have determined the atomic structure of a protein that the Lassa fever virus uses to make copies of itself within infected cells.

15 Nov 2011

Alcohol-based hand sanitizer helps reduce influenza A in children

A hand and respiratory hygiene program including frequent use of alcohol-based hand sanitizer helps reduce illness caused by influenza A and missed school days in elementary school children, reports a study in the November issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

15 Nov 2011

Possible link between norovirus and food allergies

Researchers at the Medical College of Wisconsin have found a possible link between norovirus, a virus that causes "stomach flu" in humans, and food allergies.

15 Nov 2011

Annual European CDC report says infectious diseases, drug resistance are concerns

"Europe's health is suffering, with around 80,000 cases of tuberculosis infection a year and serious problems with measles, HIV and threats from 'superbug' infections, an annual health report" from the European Centre for Disease Prevention and Control (ECDC) said Thursday, Reuters reports.

11 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

POPG inhibits influenza infections in cell cultures and mouse models

A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.

10 Nov 2011

Clinton expresses U.S. commitment to creating 'AIDS-free generation,' calls on world to help

Secretary of State Hillary Rodham Clinton, speaking at the NIH on Tuesday, "called on the world to create the first 'AIDS-free generation' by using antiviral drugs, condoms, circumcision and other approaches to stem the spread of HIV," the Washington Post reports.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Powerful monitoring tool to track spread of seasonal flu

A powerful monitoring tool that will allow researchers to track the spread of seasonal flu launches today. This year the UK Flusurvey will, for the first time, join a European network of online surveys, gathering information on how the illness spreads across the continent and enabling comparison between the different countries.

9 Nov 2011

Two decades since Magic Johnson’s HIV announcement

It is 20 years since basket ball legend Earvin ‘Magic’ Johnson, now 52 years-old, retired from the Lakers basketball team while announcing his diagnosis of HIV, a virus that causes AIDS.

8 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Children's Hospital project to investigate effectiveness of BET antagonists against HIV

Terri Finkel, M.D., Ph.D., chief of Rheumatology at Children's Hospital and Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, will pursue an innovative global health research project, titled "Use of a BET Antagonist to Control and Cure HIV Infection."

8 Nov 2011

Live virus used in polio vaccine can evolve and infect, warns TAU researcher

Health professionals and researchers across the globe believe they are on the verge of eradicating polio, a devastating virus which can lead to paralysis and death. Despite successful eradication in most countries, there are still four countries where the virus is considered endemic -- and many more in which the virus still lurks.

8 Nov 2011

Georgia Tech/CDC project focuses on microneedle patches for polio vaccination

Mark Prausnitz, Regents' professor in Georgia Tech's School of Chemical and Biomolecular Engineering, will pursue an innovative global health research project focused on using microneedle patches for the low-cost administration of polio vaccine through the skin in collaboration with researchers Steve Oberste and Mark Pallansch of the US Centers for Disease Control and Prevention.

8 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011

Economic burden of chronic hepatitis C-related liver disease

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

8 Nov 2011

CRCHUM researcher receives Gates Foundation grant to eradicate HIV/AIDS

The Centre de recherche du Centre hospitalier de l'Universit- de Montr-al (CRCHUM) announced today that one of its researchers will receive funding of 100,000 US $ through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges.

7 Nov 2011